Last reviewed · How we verify
Emtricitabine plus adefovir dipivoxil
Emtricitabine plus adefovir dipivoxil, marketed by the Asian-Pacific Alliance of Liver Disease, Beijing, holds a position in the treatment landscape for liver diseases. The drug's key composition patent is set to expire in 2028, providing a period of market exclusivity and potential revenue stability. However, the lack of detailed primary trial results and revenue data poses a significant risk in assessing its long-term market viability and competitive edge.
At a glance
| Generic name | Emtricitabine plus adefovir dipivoxil |
|---|---|
| Also known as | Brand name of emtricitabine：Huierding |
| Sponsor | Asian-Pacific Alliance of Liver Disease, Beijing |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B (PHASE3)
- A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B (PHASE3)
- Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients (PHASE4)
- Treatment of Persistent Viremia (Virus in Blood) in Chronic Hepatitis B Subjects Already Receiving Adefovir Dipivoxil (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: